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482note that in INFUSE-MI (Intracoronary Abciximab Infusion and
Aspiration Thrombectomy in Patients Undergoing Percutaneous
Coronary Intervention for Anterior ST-Segment Elevation
Myocardial Infarction) even with the use of a dedicated local drug
delivery balloon in high-risk patients with anterior ST-segment
elevation myocardial infarction presenting early (<4 h) the
magnitude of the absolute infarct size reduction with intracoronary
abciximab versus no abciximab was modest and was not ac-
companied by other markers of reperfusion success (5). Therefore,
further studies are needed to clarify the additional value of super-
selective intracoronary delivery of abciximab.*Ingo Eitel, MD
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Ruwald et al. (1) performed a non–pre-speciﬁed subgroup analysis
of patients enrolled in MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation Trial with Cardiac Resynchronization
Therapy) who received either carvedilol or metoprolol. They
concluded that carvedilol was associated with a 30% reduction in
hospitalization for heart failure or death when compared to meto-
prolol (1). However, they have not emphasized the following:
1. The presence of signiﬁcant differences in baseline charac-
teristics that heavily favor carvedilol. In the metoprolol
group and compared to the carvedilol group there were more
men (79% vs. 71%) (2), patients were older (65 vs. 63.5 years
of age) (3), and patients had higher prevalences of ischemicetiology (65% vs. 47%) (4) and prior myocardial infarction
(53% vs. 37%), with a higher burden of ischemia as evident
by higher prevalences of coronary artery bypass (34% vs.
25%) as well as non-coronary artery bypass revascularization
(32% vs. 24%). Moreover, they had signiﬁcantly more
hospitalization in the prior year (53% vs. 43%) (5). In
addition, they had a signiﬁcantly higher prevalence of
systolic blood pressure >140 mm Hg (21% vs. 16%). All of
these factors combined could have heavily inﬂuenced the
outcomes in favor of carvedilol.
2. The authors stated that 12% of those on metoprolol used the
metoprolol tartrate preparation. Considering the absence of
data from randomized trials documenting improvement in
survival or reduction of hospitalization with metoprolol
tartrate (6), these patients should have been excluded from
analysis.
3. The causes of switching from carvedilol to metoprolol need
to be ascertained. Was it because of low blood pressure? Was
there clustering of events in these patients? Regardless,
patients (n ¼ 92) who were changed from 1 type to the other
should have been excluded. It is virtually impossible to place
them in either group with certainty.
In addition, comparing the low dose of beta-blockers in the
MADIT-CRT to that in either OPTIMIZE-HF (Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients
with Heart Failure) or COPERNICUS (Carvedilol Prospective
Randomized Cumulative Survival) is somewhat inappropriate as
the dose of beta-blockers is expected to be lower in hospitalized
patients and in patients with advanced heart failure.
Finally, would the authors care to speculate on a potential mech-
anism for the suggested synergistic effect of carvedilol in patients
with left bundle branch block?*Jalal K. Ghali, MD
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444–53.ReplyWe read with interest the comments on our study (1) by Dr. Ghali.
Dr. Ghali felt we did not emphasize the differences in baseline
characteristics between patients on metoprolol and carvedilol.
Because our study was not a randomized trial to evaluate a com-
parison between metoprolol and carvedilol, we carried out a fully
adjusted multivariate Cox regression model and an additional
propensity scored-adjusted analysis. As we explained in the article,
we adjusted the multivariate model for baseline characteristics that
had a signiﬁcant impact on the endpoint of hospitalization for heart
failure or death (Table 2 in our article). This approach does not
eliminate unmeasured confounding, as we pointed out in the limi-
tations section. Therefore, the differences in the baseline character-
istics between patients on metoprolol and carvedilol as mentioned by
Dr. Ghali are taken into account in our analysis.
Dr. Ghali felt that the 12% of patients on metoprolol tartrate
should be excluded from the analysis since it has not been docu-
mented to reduce survival or hospitalization in a randomized trial.
Because some of the patients changed from tartrate to succinate (or
to carvedilol or came off the drug) throughout the study we wanted
to include and keep these patients in the analysis. Because we used
time-dependent analysis, thus always taking into account the risk
time the patient was on a particular beta-blocker with a speciﬁc
dose, we kept these patients in the analysis. If we exclude the
patients on metoprolol tartrate at baseline, the results on the
endpoint of heart failure or death were, however, similar and re-
mained statistically signiﬁcant.Regarding question 3, we used time-dependent analysis. This
means that throughout follow-up, we are taking into account the risk
time the patient is on a speciﬁc drug (at a speciﬁc dose) and its
contribution to the overall risk of the endpoint. Thus, if a patient
decided to go off the drug or change frommetoprolol to carvedilol or
the opposite, the risk time contributed on either drug is taken into
account in the analysis. Therefore, we think it wouldwrong to exclude
these patients from the analysis. We do not have precise information
on the cause of why patients changed type of beta-blocker.
Finally, we believe that the synergistic effect seen in patients
treated with carvedilol who had a left bundle branch block may be
related to favorable reverse remodeling associated with the use of
resynchronization therapy in combination with carvedilol.*Martin H. Ruwald, MD
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